BETHESDA, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (Amex:RGN) (www.regenerx.com) reported today that researchers at the Wayne State University School of Medicine and the Kresge Eye Institute in Detroit, Michigan, found that thymosin beta 4 (Tß4) inhibits the activation and nuclear translocation of the transcription factor NF?B, (pronounced: N-F-kappa-B), widely implicated as a major regulator of inflammatory response. The research team, headed by Gabriel Sosne, M.D., Assistant Professor of Ophthalmology and Anatomy/Cell Biology at the Kresge Eye Institute, of the Wayne State University School of Medicine, published their latest findings in Experimental Eye Research, January 23, 2007. Dr. Sosne is a member of RegeneRx’s Medical and Scientific Advisory Board.
